12:31 , Jun 13, 2019 |  BioCentury  |  Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders. New investors Polaris Partners,...
10:08 , Apr 30, 2019 |  BioCentury  |  Finance

How Nextech-led round will help Vividion to POC

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest. Now flush with over...
17:33 , Mar 8, 2019 |  BC Week In Review  |  Financial News

Beam raises $135M series B

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May...
12:11 , Mar 6, 2019 |  BioCentury  |  Finance

Beam broadens base with $135M B round

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May...
18:33 , Dec 14, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience merge, raise $50M

Emerging from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc., Millendo Therapeutics Inc. (NASDAQ:MLND) raised $49.5 million in a financing Friday. The combined company will begin trading...
17:50 , Dec 7, 2018 |  BC Extra  |  Company News

Millendo, OvaScience merge, raise $50M

Emerging from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc., Millendo Therapeutics Inc. (NASDAQ:MLND) raised $49.5 million in a financing Friday. The combined company will begin trading...
06:12 , Aug 10, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience reverse merging

Fertility company OvaScience Inc. (NASDAQ:OVAS) will reverse-merge with endocrine play Millendo Therapeutics Inc. (Ann Arbor, Mich.) in an all-stock deal. The resulting company will focus on developing Millendo's pipeline for orphan indications. New Enterprise Associates,...
17:17 , Aug 3, 2018 |  BC Week In Review  |  Financial News

Omniome raises $60M series B

DNA sequencing company Omniome Inc. (San Diego, Calif.) raised $60 million on July 30 in a series B round led by new investors Decheng Capital and Hillhouse Capital Group. New investors Lam Research Capital and...
00:24 , Aug 3, 2018 |  BioCentury  |  Finance

Appetite for Omniome

An experienced team and a growing DNA sequencing market in China enabled San Diego’s Omniome Inc. to raise a $60 million series B round led by Chinese investors. Decheng Capital and Hillhouse Capital Group co-led...
22:53 , Jul 30, 2018 |  BC Extra  |  Financial News

Omniome raises $60M series B

DNA sequencing company Omniome Inc. (San Diego, Calif.) raised $60 million in a series B round led by new investors Decheng Capital and Hillhouse Capital Group. New investors Lam Research Capital and Nan Fung Life...